Elyxium Wealth’s Rani Therapeutics RANI Stock Holding History

Elyxium Wealth’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-760	Closed	-$1.03K	–	1007
2025 Q4	$1.03K	Buy	+760	New	+$1.15K	﹤0.01%	1201

Other funds holding RANI

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM

Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Elyxium Wealth's RANI Position: Q1 2026 in Review

Elyxium Wealth sold out of Rani Therapeutics (RANI) in Q1 2026, closing a stake of 760 shares — an estimated $1.03K sold.

Elyxium Wealth first reported a position in RANI in Q4 2025 and held it in 1 quarter. The position peaked at $1.03K in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

Elyxium Wealth reported no remaining Rani Therapeutics position as of Q1 2026 after selling out during the quarter.
Elyxium Wealth sold 760 Rani Therapeutics shares in Q1 2026, an estimated $1.03K.
Elyxium Wealth first reported a position in Rani Therapeutics in Q4 2025 and held it in 1 quarter.
Elyxium Wealth's Rani Therapeutics position peaked at $1.03K in Q4 2025.
74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Elyxium Wealth's 13F filing for Q1 2026, filed 6 May 2026.